The medicine isn’t the treatment
Dr Nick Brüss is a psychotherapist and clinical researcher who has spent years working where mental health research meets practice. He served as a clinician and supervisor on the MAPS phase 3 study of MDMA-assisted therapy for PTSD, worked on COMPASS research using psilocybin for treatment-resistant depression, and works with ketamine in private practice. He was a long-time meditator and mindfulness practitioner before any of it.
He is careful, and the caution is the most useful thing he says. These medicines are not a silver bullet and not a panacea. It is not a matter of taking a pill, or eating a mushroom, and being better. What produces the result, in his account, is a person willing to show up, go inward, and then do the work of preparation and integration around the session — which is where most of the therapy actually happens.
The clinical picture he describes is specific rather than sweeping. In the MDMA trial, participants were not people with everyday stress: on average they had lived with PTSD for fourteen years, and many had to come off existing medication to take part. After three dosing sessions across three months, roughly two-thirds no longer met the criteria for PTSD. The FDA has designated both MDMA and psilocybin as breakthrough therapies.
His broader argument is why he belongs in a project about longevity at all. A great many people, he says, are not resisting the idea of more years — they are quietly not sure they want them. Where the default mindset is threat-scanning and self-protection, the work is a shift toward being open, curious and willing to feel. That is a longevity intervention as much as anything measured in a lab.
